We are live on ! Find out more
NVO

Novo Nordisk

707 hedge funds and large institutions have $8.87B invested in Novo Nordisk in 2021 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 259 increasing their positions, 210 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more repeat investments, than reductions

Existing positions increased: 259 | Existing positions reduced: 210

21% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 56

1% more funds holding

Funds holding: 702707 (+5)

0% more funds holding in top 10

Funds holding in top 10: 77 (0)

0.5% less ownership

Funds ownership: 15.06%14.56% (-0.5%)

7% less capital invested

Capital invested by funds: $9.54B → $8.87B (-$665M)

21% less call options, than puts

Call options by funds: $21.8M | Put options by funds: $27.5M

Holders
707
Holders Change
+5
Holders Change %
+0.71%
% of All Funds
12.41%
Holding in Top 10
7
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
68
Increased
259
Reduced
210
Closed
56
Calls
$21.8M
Puts
$27.5M
Net Calls
-$5.73M
Net Calls Change
-$19.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Thrivent Financial for Lutherans
26
Thrivent Financial for Lutherans
Minnesota
$58M +$4.75M +133,402 +8%
UCFA
27
United Capital Financial Advisors
Texas
$55.7M -$1.15M -32,332 -2%
First Trust Advisors
28
First Trust Advisors
Illinois
$55.6M +$4.96M +139,298 +9%
Morgan Stanley
29
Morgan Stanley
New York
$52M -$25M -701,190 -31%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$49.5M -$578K -16,228 -1%
Baird Financial Group
31
Baird Financial Group
Wisconsin
$42.2M +$449K +12,602 +1%
AAMU
32
Amundi Asset Management US
Massachusetts
$36.2M -$48M -1,347,118 -56%
Jennison Associates
33
Jennison Associates
New York
$32.9M -$12.8M -359,168 -27%
Truist Financial
34
Truist Financial
North Carolina
$30.4M +$1.87M +52,534 +6%
Two Sigma Investments
35
Two Sigma Investments
New York
$30.3M -$7.26M -203,952 -18%
UBS Group
36
UBS Group
Switzerland
$30.2M +$228K +6,414 +0.7%
Alyeska Investment Group
37
Alyeska Investment Group
Illinois
$28.7M +$30.3M +850,000 New
Fidelity Investments
38
Fidelity Investments
Massachusetts
$26M +$1.73M +48,626 +7%
Franklin Resources
39
Franklin Resources
California
$25.8M +$1.12M +31,466 +4%
JP Morgan Chase
40
JP Morgan Chase
New York
$24.7M +$758K +21,284 +3%
Millennium Management
41
Millennium Management
New York
$23.7M +$25M +702,818 New
Bank of New York Mellon
42
Bank of New York Mellon
New York
$22.8M +$3M +84,300 +14%
Invesco
43
Invesco
Georgia
$22.2M -$854K -23,984 -4%
OAM
44
Oppenheimer Asset Management
New York
$20.1M +$2.03M +57,078 +11%
PFM
45
Parsec Financial Management
North Carolina
$19.2M -$846K -23,748 -4%
PNC Financial Services Group
46
PNC Financial Services Group
Pennsylvania
$18M -$11.3M -315,884 -37%
EVM
47
Eaton Vance Management
Massachusetts
$17.9M -$14.1M -395,520 -43%
NPA
48
Nichols & Pratt Advisers
Massachusetts
$17.8M -$38.1K -1,070 -0.2%
CL
49
CIM LLC
New York
$16.7M -$275K -7,734 -2%
BIAS
50
Beacon Investment Advisory Services
New Jersey
$16.7M -$260K -7,300 -1%

NVO Hedge Fund Activity: Q1 2021 in Review

707 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2021, worth a combined $8.87B — down 7% from $9.54B a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new NVO positions and 56 closed out — a net gain of 12 holders — while 259 added to existing stakes and 210 trimmed.

The largest buyer was BlackRock, adding an estimated $132M. The largest seller was Renaissance Technologies, cutting an estimated $142M.

  • 707 institutional investors held Novo Nordisk (NVO) as of Q1 2021, up from 702 in Q4 2020.
  • Funds reported $8.87B of Novo Nordisk stock for Q1 2021, down 7% quarter-over-quarter.
  • 68 funds opened new Novo Nordisk positions in Q1 2021 and 56 closed out, a net change of +12 holders.
  • The largest Novo Nordisk buyer in Q1 2021 was BlackRock, an estimated $132M added.
  • The largest Novo Nordisk seller in Q1 2021 was Renaissance Technologies, an estimated $142M sold.

Based on aggregated 13F filings for Q1 2021.